(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 6. Lower level reduction of FGF8a and FGF8b or strong
reduction of FGF8a alone with XlMOF8, MOSDF8 and MOSAF8a prevents
proper formation of posterior neural tissue at the early neurula stage.
X. laevis embryos displayed dorsoanteriorly. Pink staining indicates
the lineage tracer; embryos injected into one cell at the two- or four-cell
stage. (A,E,I,M) Control MO (40 ng); (B,F,J,N) MOF8 20 ng; (C,G,K,O) MOSDF8 43
ng; (D,H,L,P) MOSAF8a 60 ng. (A-D) XlMOF8 (44/45), MOSDF8 (18/19) and
MOSAF8a (38/39) cause a mispatterning of sox2 expression.
(E-H) otx2 expression is expanded toward the posterior after
XlMOF8 (23/25), MOSDF8 (20/20) and MOSAF8a (26/29) injection, while the
posterior neural gene dbx is absent (MOF8, 25/25; MOSDF8, 20/20;
MOSAF8a, 35/38). (I-L) en2 expression is diminished and
sometimes completely absent on the injected side: XlMOF8 (13/13), MOSDF8
(17/17) and MOSAF8a (32/33). (M-P) both the spinal cord domain
(hoxB9) and the hindbrain domain (krox20) is strongly
reduced and shifted toward the posterior of the embryo on the XlMOF8 (42/42),
MOSDF8 (20/20) and MOSAF8a (40/40) injected side of the embryo. Effects on the
uninjected side are present but much weaker. (Q-S) Neural tube stage 20
embryos treated as indicated; (T-V) FGF8a mRNA (50 pg) rescued the
reduction of hoxB9 caused by XlMOF8 (32/44), MOSAF8a (19/35) and MOSDF8
(19/20).